Summary
Medroxyprogesterone acetate plasma levels were measured in advanced cancer patients after multiple PO or IM administration (500, 1000, 2000, 3000, 4000, and 5000 mg/day PO and 500, 1000, 2000 mg/day IM for 30 days). After PO administration, the plasma concentration rises quickly and plateau level is reached in 4–10 days. Discontinuation of the treatment produces a fast decay (t1/2=62.4 h) of the drug levels. When medroxyprogesterone acetate is given IM plasma levels steadily increase and after drug discontinuation no noticeable decay is observed for at least 6 months; plateau plasma levels are about three times higher than after the corresponding PO treatment. Extremely high interpatient variation in bioavailability is present with both administration routes. These data may well rationalize the results of previous clinical trials and will help in planning treatment schedules.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Blossey HC, Bartsch HH, Kanne D, Koebberling J, Nagel GA (1982) The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer. Cancer Chemother Pharmacol 8: 77–81
Breslow N (1970) A generalized Kruskal-Wallis test for comparing k samples subject to unequal patterns of censorship. Biometrika 57: 579–594
Cavalli F, Goldhirisch A, Kaplan E (1981) High (H) versus low (L) dose medroxyprogesterone acetate (MPA) in advanced breast cancer. In: Proceedings the European Society for Medical Oncology Conference. p 32
Cornette JC, Kirton KT, Duncan GW (1971) Measurement of medroxyprogesterone acetate (Provera) by radioimmunoassay. J Clin Endocrinol 33: 459–66
De Lena M, Brambilla G, Valagussa P, Bonadonna G (1979) High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy. Cancer Chemother Pharmacol 2: 175–180
Dixon WJ, Brown MB (1979) BMDP-79 biomedical computer programs, P-series. University of California Press, Berkeley
Iacobelli S, Natoli C, Sica G, Gaggini C (1982) Common and distinct features in the growth-inhibitory activity of MPA and tamoxifen on estrogen-sensitive human breast cancer cells. In: International Symposium on Medroxyprogesterone Acetate. Excerpta Medica, Amsterdam, pp 80–87
Kaiser DG, Carlson RG, Kirton KT (1974) GLC determination of medroxyprogesterone acetate in plasma. J Pharm Sci 63: 420–424
Mantel N (1966) Evaluation of survival data and two new rank order statistic arising in its consideration. Cancer Chemother Rep 50: 163–170
Mattson W (1978) High-dose medroxyprogesterone acetate treatment in advanced mammary carcinoma. A phase II clinical study. Acta Radiol Oncol 17: 337–340
McGuire JL, Bariso CD, Shroff AP (1979) Interaction between steroids and a uterine progesteron specific binding macromolecule. Biochemestry 13: 319–322
Pannuti F, Martoni A, Lenaz GR, Piana E, Nanni P (1976) Management of advanced breast cancer with medroxyprogesterone acetate (MPA, F.I. 5837, F.I. 7401, NSC-26386) in high doses. In: Colin C, Franchimont P, Gordenne W, Juret P, Lambotte R, Lavigne J, Leroux GF, Stoll BA, Vokaer R (eds) Functional exploration in senology. European Press, Ghent, pp 235–265
Pannuti F, Martoni A, Lenaz GR, Piana E, Nanni P (1978a) A possible new approach to the treatment of metastatic breast cancer: Massive doses of medroxyprogesterone acetate. Cancer Treat Rep 62: 499–504
Pannuti F, Martoni A, Di Marco AR, Piana E, Saccani F, Becchi G, Mattioli G, Barbanti F, Marra GA, Persiani W, Cacciari L, Spagnolo F, Palenzona D, Rocchetta G (1978) Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MPA) in the treatment of metastatic breast cancer. Eur J Cancer 15: 593–601
Pannuti F, Martoni A, Fruet F, Burroni P, Canova N, Hall S (1982a) Oral high-dose medroxyprogesterone acetate versus tamoxifen in postmenopausal patients with advanced breast cancer. In: Iacobelli S, Lippmann ME, Robustelli Della Cuna G (eds) The role of tamoxifen in breast cancer. Raven Press, New York, pp 85–93
Pannuti F, Martoni A, Camaggi CM, Strocchi E, Di Marco AR, Rossi AP, Tomasi L, Giovannini M, Cricca A, Fruet F, Lelli G, Giambiasi ME, Canova N (1982b) High-dose medroxyprogesterone acetate in oncology. History, clinical use and pharmacokinetics. In: International Symposium on Medroxyprogesterone Acetate. Excerpta Medica, Amsterdam, pp 5–43
Pannuti F, Camaggi CM, Strocchi E, Giovannini M, Di Marco AR, Costanti B (1982c) Medroxyprogesterone Acetate (MPA); Relative bioavailability after single high-dose administration in cancer patients. Cancer Treat Rep 66: 2043–2049
Pannuti F, Camaggi CM, Strocchi E, Giovannini M, Canova N, Murari G (1982d) Medroxyprogesterone acetate (MPA) plasma levels after simultaneous oral and intramuscular administration in cancer patients. Cancer Chemother Pharmacol 9: 122–123
Pannuti F, Camaggi CM, Strocchi E, Giovannini M, Costanti B (1983) Medroxyprogesterone acetate plasma pharmacokinetics after high-dose oral or intraperitoneal administration in advanced cancer patients. Cancer Chemother Pharmacol (in press)
Pannuti F, Gentili MR, Camaggi CM, et al. (1983) Medroxyprogesterone acetate (MPA): Massive oral doses in advanced breast cancer management. A feasibility study. Cancer Treat Rep (in press)
Robustelli Della Cuna G, Calciati A, Bernardo-Strada MR, Bumma C, Campio L (1978) High-dose medroxyprogesterone acetate (MPA) treatment in metastatic carcinoma of the breast: a dose-response evaluation. Tumori 64: 143–149
Shrimanker K, Saxena BN, Fotherby K (1978) A radioimmunoassay for serum medroxyprogesterone acetate. J Steroid Biochem 9: 359–363
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Camaggi, C.M., Strocchi, E., Giovannini, M. et al. Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients. Cancer Chemother. Pharmacol. 11, 19–22 (1983). https://doi.org/10.1007/BF00257410
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00257410